Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T
TPST•Development collaboration with Senlang Biotechnology
July 21 (Reuters) - Tempest Therapeutics Inc TPST.O:
- Tempest announces development collaboration with Senlang Biotechnology for TPST-4003, a CD7-targeted next-generation in vivo CAR-T.
- Tempest Therapeutics said first patient dosing for the TPST-4003 trial is expected in Q4 2026.
- The company and Senlang will develop TPST-4003 with a trial in China for MG and MS.
Source text: ID:nGNX9T07mm
Further company coverage: TPST.O
